Across TCGA pan-cancer cohorts, ADCYAP1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ADCYAP1 data layer compared with 24 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADCYAP1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADCYAP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
PDAC and LUAD are the cancer types where ADCYAP1 mass-spec protein most reproducibly stratifies survival.